Claims for Patent: 10,406,209

Summary for Patent: 10,406,209

Title:	Sialic acid derivatives for protein derivatisation and conjugation
Abstract:	Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
Inventor(s):	Sanjay Jain, Peter Laing, Gregory Gregoriadis, Dale Howard Hreczuk-Hirst, Ioannis Papaioannou
Assignee:	Lipoxen Technologies Ltd
Application Number:	US15/276,471

Details for Patent 10,406,209

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Inc.	AGRIFLU	influenza virus vaccine	Injection	125297	November 27, 2009	10,406,209	2036-09-26

International Patent Family for US Patent 10,406,209

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2006016161
World Intellectual Property Organization (WIPO)	2005016974
World Intellectual Property Organization (WIPO)	2005016949
United States of America	9828443
United States of America	9790288
United States of America	9452224
United States of America	9200052